Waiting for a pandemic

  • Rino Rappuoli
  • Giuseppe Del Giudice
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)


After a quiet period of nearly 30 years, influenza strains with hemagglutinin types that have not been seen in humans previously started to jump from birds to man, suggesting the risk of a new influenza pandemic. However, in contrast to the situation with all the other influenza pandemics occurring in the 20th century and before, in the 21st century we have sophisticated technologies for diagnosis, therapy and prevention. Modeling of the possible spread of a pandemic suggests that vaccination is by far the only way to eliminate the risk of a new pandemic. In this chapter we review the development of new vaccines against H5N1 viruses, showing that effective vaccines adjuvanted with oil-inwater emulsion are about to be licensed and will soon be available. The race against an influenza pandemic has begun; it is a battle against time that mankind cannot afford to lose.


Influenza Vaccine Influenza Pandemic ADJUVANTED Vaccine Split Vaccine UENZA Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K (2004) The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci USA 101: 10452–10457PubMedCrossRefGoogle Scholar
  2. 2.
    Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M et al (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028–6036PubMedCrossRefGoogle Scholar
  3. 3.
    Luke CJ, Subbarao K (2006) Vaccines for pandemic influenza. Emerg Infect Dis 12: 66–72PubMedGoogle Scholar
  4. 4.
    Suguitan, AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3: e360PubMedCrossRefGoogle Scholar
  5. 5.
    Novavax Inc (2007) Press release Novavax announces preclinical results for seasonal influenza vaccine program Google Scholar
  6. 6.
    De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W (2005) Universal influenza A vaccine: Optimization of M2-based constructs. Virology 337: 149–161PubMedCrossRefGoogle Scholar
  7. 7.
    De Filette M, Fiers W, Martens W, Birkett A, Ramne A, LÖwenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597–6601PubMedCrossRefGoogle Scholar
  8. 8.
    Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ et al (2007) Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccines 3: 157–164Google Scholar
  9. 9.
    Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426–435PubMedCrossRefGoogle Scholar
  10. 10.
    Livingston BD, Higgins D, Van Nest G (2006) Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 20: 335–340PubMedCrossRefGoogle Scholar
  11. 11.
    Nicholson KG, Colgate AE, Podda A, Stephenson I, Wood J, Ypma Y, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–1943PubMedCrossRefGoogle Scholar
  12. 12.
    Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21: 1687–1693PubMedCrossRefGoogle Scholar
  13. 13.
    Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 191: 1210–1215PubMedCrossRefGoogle Scholar
  14. 14.
    Schwatz B, Gellin B (2005) Vaccination strategies for an influenza pandemic. J Infect Dis 191: 1207–1209CrossRefGoogle Scholar
  15. 15.
    Zangwill K, Campbell J, Noah D, Treanor J (2007) Evaluation of a third dose of subvirion H5N1 influenza vaccine (rgA/Vietnam/1203/04xPRB) in healthy adults. In: Options for the Control of Influenza VI (Toronto, June 17-23, 2007). Abstract no. P737Google Scholar
  16. 16.
    Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343–1351PubMedCrossRefGoogle Scholar
  17. 17.
    Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O’Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732–1737PubMedCrossRefGoogle Scholar
  18. 18.
    Bresson JL, Perronne L, Leunay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomized trial. Lancet 367: 1657–1664PubMedCrossRefGoogle Scholar
  19. 19.
    Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370: 580–589PubMedCrossRefGoogle Scholar
  20. 20.
    Banzhoff A (2007) Antigen-sparing effect of MF59 in Fluad-H5N1. In: Third WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 157#x2013;16 February 2007, WHO, GenevaGoogle Scholar
  21. 21.
    Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z et al (2006) Safety and immunogenicity of an inactivated adjuvanted wholevirion influenza A (H5N1) vaccine: A Phase I randomised controlled trial. Lancet 368: 991–997PubMedCrossRefGoogle Scholar
  22. 22.
    Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I (2007) Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13: 807–808PubMedGoogle Scholar
  23. 23.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135–1142PubMedCrossRefGoogle Scholar
  24. 24.
    Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209–214PubMedCrossRefGoogle Scholar
  25. 25.
    Germann TC, Kadau K, Longini IM Jr, Macken CA (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103: 5935–5940PubMedCrossRefGoogle Scholar
  26. 26.
    Flahault A, Vergu E, Coudeville L, Grais RF (2006) Strategies for containing a global influenza pandemic. Vaccine 24: 6751–6755PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Rino Rappuoli
    • 1
  • Giuseppe Del Giudice
    • 1
  1. 1.Novartis Vaccines and DiagnosticsSienaItaly

Personalised recommendations